News

Reported reasons adults had not received a bivalent COVID-19 booster dose differed across age groups.

Click on the slideshow images to read the full stories featured in this weekly infectious disease recap.

A mathematical modeling study for HPTN 083 demonstrated both forms of PrEP vs not taking anything remained efficacious in preventing infection.

Although vaccine rates overall remain high, a new report shows a reduction 2 years in a row, leaving thousands of children not vaccinated against vaccine-preventable viruses.

Tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF), antiretroviral drugs used to treat HIV and hepatitis B, may be simultaneously depleting the energy of immune cells.

A retrospective study showed that exercise was found to have a protective association to adverse COVID-19 outcomes.

What is the hepatitis C treatment uptake among people who inject drugs?

Interleukin-6 receptor antagonists and antiplatelets are highly likely to improve long-term survival of critically ill adults with COVID-19, a recent study suggests.

Based on the Data and Safety Monitoring Board DSMB’s recommendation, the study will be discontinued.

With limited health care infrastructure and large swaths of remote areas, developing countries face difficulties in medical management with these viruses and parasitic diseases.

Therapies to reach a functional cure for hepatitis B virus may differ among the phases of hepatitis B, including new antiviral agents and immunomodulatory strategies, the study authors predicted.

This act designed to allow pharmacists and technicians the ability to administer certain vaccines without a prescriber order will lapse next year. A new report looks at vaccination trends in the US and how pharmacists are playing a vital role in administering vaccines.

With these results, the company plans to submit their investigational vaccine, MRNA-1345, for regulatory approval in the first half of 2023.

Tibetan Buddhist monks, who meditate regularly, had vastly different gut microbiomes than the non-meditating control group.

In this guest editorial, the author talks about the challenges associated with dealing with both health issues.

High levels of mucosal IgA antibodies in the airways were found to protect against COVID-19 reinfection for at least 8 months.

Preclinical testing suggests that a newly developed SARS-CoV-2 vaccine could protect against current and future variants.

This live-attenuated investigational vaccine was developed by Codagenix, which uses its codon de-optimization platform for its candidates.

Fecal microbiota transplantation (FMT) is known to be an effective treatment for recurrent Clostridioides difficile infection. New research reveals why.

A CDC report looked at 2 vaccine safety surveillance systems for the bivalent boosters in this population and there were no reports of myocarditis or death. Many of the reports were due to vaccine errors and not adverse events.

The two agencies said one of the vaccine surveillance systems prompted an investigation into whether there was a safety concern for ischemic stroke in seniors for this booster.

The therapies for Clostridioides difficile infection (CDI) saw many developments in recent months and there are more exciting things to come.

It's Friday the 13th, but you can counteract bad luck by catching up on this week's top infectious disease news.

A randomized trial found the antidepressant to be ineffectual in helping improve time to sustained recovery.

Fecal microbiota transplant (FMT) is a promising option for patients struggling with CDI recurrences. But how can we ensure the treatment is successful?

A 2-year retrospective study looking at patients admitted to the ICU showed that the number of intubated males infected with Acinetobacter baumannii (AB) was double the number of intubated females.

Recent numbers show a lack of new people entering the field combined with existing shortfalls in many US locations.These factors demonstrate a potentially dangerous reduction in this vital medical specialty.

Clostridioides difficile (CDI) and recurrence can create a tremendous burden on patients’ quality of life as well as become a financial burden to individual healthcare systems thus creating downstream costs for individual hospitals.